← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins
cefoperazone and beta-lactamase inhibitor
J01DD62
Forms & Strengths
- Powder for injection: Cefoperazone 1g / Sulbactam 1g per vial
- Powder for injection: Cefoperazone 0.5g / Sulbactam 0.5g per vial
- Powder for injection: Cefoperazone 2g / Sulbactam 1g per vial
Adult Dosing
- Standard dose: 2g to 4g daily (total combined drug) administered in divided doses every 12 hours
- Severe or refractory infections: Up to 8g daily (divided into doses every 8 to 12 hours)
- Maximum daily dose of sulbactam should not exceed 4g
Pediatric Dosing
- Neonates (first week of life): 40 to 80 mg/kg/day divided every 12 hours
- Infants and children: 40 to 80 mg/kg/day divided every 6 to 12 hours
- Severe infections: Up to 160 mg/kg/day divided in equal doses
Indications
- Respiratory tract infections caused by susceptible beta-lactamase producing strains
- Urinary tract infections
- Intra-abdominal infections including peritonitis
- Septicemia, skin and soft tissue infections, pelvic inflammatory disease
Mechanism of Action
- Cefoperazone: Third-generation cephalosporin inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins
- Sulbactam: Irreversible beta-lactamase inhibitor protecting cefoperazone from degradation by plasmid- and chromosomally-mediated beta-lactamases
Contraindications
- Known hypersensitivity to cefoperazone, sulbactam, or any cephalosporin class antibiotics
- History of severe allergic reactions to penicillin derivatives
Adverse Reactions
- Diarrhea and pseudomembranous colitis
- Hypoprothrombinemia and bleeding disorders due to N-methylthiotetrazole side chain
- Disulfiram-like ethanol reaction
- Transient elevations in liver transaminases and alkaline phosphatase
- Injection site pain and phlebitis
Drug Interactions
- Alcohol: Induces disulfiram-like reaction (flushing, sweating, headache, tachycardia) up to 72 hours post-administration
- Anticoagulants (warfarin, heparin): Increased risk of severe hemorrhage due to additive hypoprothrombinemic effects and platelet inhibition
- Aminoglycosides: Incompatible in physical mixture; must be administered at separate sites with adequate flushing
Curated Content: Needs Vetting Before Put to Clinical Use